The HEALEY ALS Platform Trial is enrolling people living with Amyotrophic Lateral Sclerosis(ALS) to test the efficacy of multiple investigational products. The Platform Trial is designed to decrease the time it takes to test new potential therapies and increase access to research forpeople living with ALS. One of the innovative features of the Platform Trial is that enrollment will continue as more investigational products are added. For more information about the Healey ALS Platform trial, see this article for links to general information and for FAQs about the trial.
Researchers at Oregon State University have announced that new therapy that stops the progression of ALS. The therapy is based on using Copper-ASTM, a compound that delivers copper specifically to cells with damages mitochondria. Full article
The FDA advisory committee recently approved the use of AMX0035 for the treatment of ALS. Presented with the robustness of new evidence, the committee reversed their March 2022 vote overwhelming by a 7-2 vote. The ALS Association has publicly thanked both the FDA advisory committee and the entire ALS community for their hard work and advocacy. Read Full Article
Amylyx Pharmaceuticals will have an FDA advisory committee to review a new drug application for AMX0035 for the treatment of ALS. For more details on the committee, see the full article in the AMYLX press release.
Learn about how the FDA has granted fast track to the approval of the APB-102 Gene Therapy in the article in the ALS News Today.
Read this article from the National Library of Medicine to learn about a case of ALS patient using modified Dihuang Yinzi (DHYZ), a classical traditional Chinese medicine (TCM) prescription. This person has survived 12 years with significant improvement in bulbar paralysis.
Clinical trials with NU-9 shows that it improves the health of UMNs. Read more in the full article from nature.com.